title: HER2-enriched tumors have the highest risk of local recurrence in Chinese patients treated with breast conservation therapy.
abstract: OBJECTIVE
  The purpose of this study was to investigate the recurrence pattern and characteristics of patients based on the 2013 St. Gallen surrogate molecular subtypes after breast-conserving surgery (BCS) in Chinese women.
  
  
  METHODS
  This retrospective analysis included 709 consecutive breast cancer patients undergoing BCS from 1999-2010 at our institution. Five different surrogate subtypes were created using combined expression of the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2. Locoregional relapse-free survival (LRRFS), distant metastasis-free survival (DMFS), and disease-free survival (DFS) rates were calculated.
  
  
  RESULTS
  The 5-year LRRFS, DMFS, and DFS rates were 90.5%, 88.2%, and 81.5%, respectively. Multivariate analysis revealed that young age, node-positive disease, and HER2 enrichment were independent prognostic factors in LRRFS patients. There was also an independent prognostic role of lymph node-positive disease in DMFS and DFS patients. Patients with luminal A tumors had the most favorable prognosis, with LRRFS, DMFS, and DFS rates of 93.2%, 91.5%, and 87.5% at 5 years, respectively. Conversely, HER-2-enriched tumors exhibited the highest rate of recurrence (27.5%) and locoregional recurrence (11.4%).
  
  
  CONCLUSIONS
  Surrogate subtypes present with significant differences in RFS, DMFS, and LRRFS. Luminal A tumors have the best prognosis, whereas HER2-enriched tumors have the poorest.
authors: Department of breast cancer, Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou, China E-mail : fengxisu@vip.163.com.
authors: Wei-Juan
authors: WJ
authors: Jia
authors: Hai-Xia
authors: HX
authors: Jia
authors: Hui-Yi
authors: HY
authors: Feng
authors: Ya-Ping
authors: YP
authors: Yang
authors: Kai
authors: K
authors: Chen
authors: Feng-Xi
authors: FX
authors: Su
mesh_terms: D000328:Adult; D000367:Age Factors; D001943:Breast Neoplasms / Q000737:chemistry* / Q000473:pathology* / Q000601:surgery; D002681:China; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D015412:Mastectomy, Segmental; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000737:chemistry*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone